Novo Nordisk has launched the Wegovy pill in the US, offering a 1.5 mg starter dose of semaglutide, expanding its weight-loss treatment options. The pill, approved by the FDA, aims to regain market share against Eli Lilly's upcoming Mounjaro pill.